{"id":"v110-pneumococcal-vaccine-polyvalent","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, swelling, or itching at the injection site"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This vaccine works by introducing inactivated pneumococcal bacteria to the body, which triggers an immune response and the production of antibodies that can help protect against future infections. The immune system then remembers these bacteria and can mount a more effective response if exposed to them again in the future.","oneSentence":"V110, pneumococcal vaccine polyvalent, stimulates the body's immune system to produce antibodies against pneumococcal bacteria.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:44.054Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive pneumococcal disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F"}]},"trialDetails":[{"nctId":"NCT00560950","phase":"PHASE3","title":"Revaccination With PNEUMOVAX(TM) 23 in Older Adults (V110-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-07","conditions":"Pneumococcal Infection","enrollment":143},{"nctId":"NCT00496093","phase":"PHASE3","title":"Safety, Tolerability and Immunogenicity of Pneumovax 23 in Healthy Adults in India (V110-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-10","conditions":"Pneumococcal Infection","enrollment":133},{"nctId":"NCT00127153","phase":"PHASE3","title":"A Study of V110 a Pneumococcal Vaccine in Healthy Adults (V110-013)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-03","conditions":"Healthy, Pneumococcal Infections","enrollment":130}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"V110, pneumococcal vaccine polyvalent","genericName":"V110, pneumococcal vaccine polyvalent","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Biologic","firstApprovalDate":"","aiSummary":"V110 is a pneumococcal vaccine polyvalent, classified as a vaccine component that induces an immune response. It is being studied in clinical trials for its safety, tolerability, and immunogenicity in healthy adults and those with pneumococcal infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}